Kymera’s KT-621 atopic dermatitis trial closes enrollment six months early
Kymera Therapeutics said its Phase 2b BROADEN2 trial of KT-621, an oral STAT6 degrader for atopic dermatitis, closed enrollment about six months early, moving topline results from mid-2027 to year-end 2026 and compressing Phase 3 start to mid-2027. The company cited Phase 1 data showing up to 98% STAT6 degradation in peripheral blood.
How this was made
The 30-second read
Why it matters
The primary new trading-relevant fact is the six-month early enrollment close for BROADEN2, which moves the expected topline readout to year-end 2026 and tightens the path to Phase 3 initiation to mid-2027. This can shift probability-weighted valuation for KT-621 and the broader platform, ahead of the key efficacy endpoint readout.
Market read
Traders may reprice Kymera’s clinical milestone calendar for KT-621 due to the materially accelerated enrollment close and the implied earlier efficacy readout window.
What to watch
The article highlights enrollment speed and Phase 1 degradation depth, but does not provide safety/tolerability details for KT-621 in Phase 2b or discuss endpoint assumptions that could drive the placebo-adjusted response.
Background
Kymera is developing oral targeted protein degraders in immunology, including KT-621 (STAT6 degrader) for atopic dermatitis, plus other programs (KT-579, KT-485) in earlier stages.
Ticker impact
Kymera’s BROADEN2 Phase 2b for KT-621 closed enrollment about six months early, shifting topline timing to year-end 2026 and compressing Phase 3 initiation to mid-2027.
Near-term upside bias as traders price earlier clinical milestones; magnitude depends on how the year-end 2026 efficacy rate compares to placebo.
The article discloses a concrete calendar acceleration and links it to a key efficacy endpoint (EASI or IGA response rate), which can change expectations for future milestone timing and risk.
Market effects
Supports the narrative that oral targeted protein degradation can compete with biologics in dermatology, potentially improving sentiment toward similar immunology degrader programs.
No clear regional market linkage beyond US-listed clinical-stage biotech sentiment.
Limited; the key impact is on Kymera’s development timeline and read-through to the broader immunology degrader space.
Counterpoint
Enrollment acceleration does not guarantee higher efficacy; if the year-end 2026 EASI/IGA response rate misses, the earlier timeline could increase disappointment risk.
Key entities
- companyKymera
Clinical-stage biotech running the BROADEN2 Phase 2b trial for KT-621 in atopic dermatitis.
- drug_programKT-621
Oral STAT6 degrader being tested in Phase 2b BROADEN2 for moderate-to-severe atopic dermatitis.
- clinical_trialBROADEN2
Phase 2b atopic dermatitis study whose enrollment closed about six months early, pulling topline timing forward.
- drug_programKT-579
IRF5 degrader in a Phase 1 healthy volunteer study with data expected in Q4 2026.
- drug_programKT-485
Second-generation IRAK4 degrader in hidradenitis suppurativa, with Sanofi dosing the first participant and a $20 million milestone triggered.
